
Phase 3 data show intismeran plus pembrolizumab reduced recurrence or death risk by 42% in patients with resected stage IIB-IV melanoma.
Click here to answer this week's poll.
At the beginning of 2023, the
Do you treat more male or female patients with melanoma?
Reference





